Sarepta Therapeutics (SRPT) Work In Process (2022 - 2026)

Sarepta Therapeutics has reported Work In Process for 5 years, with the latest figure at $981.0 million in Q1 2026.

• For the quarter ending Q1 2026, Work In Process rose 28.71% year-over-year to $981.0 million; the trailing twelve-month figure through Mar 2026 stood at $981.0 million (up 28.71% YoY), and the FY2025 full-year result was $892.7 million, up 46.18% from the prior year.
• Work In Process for Q1 2026 stood at $981.0 million, up from $892.7 million in the prior quarter.
• The five-year high for Work In Process was $981.0 million in Q1 2026, with the low at $269.2 million in Q4 2022.
• Average Work In Process over 5 years is $647.5 million, with a median of $686.5 million recorded in 2024.
• Year-over-year, Work In Process advanced 18.3% in 2023 and jumped 91.77% in 2024.
• Tracing SRPT's Work In Process over 5 years: stood at $269.2 million in 2022, then climbed by 18.3% to $318.5 million in 2023, then jumped by 91.77% to $610.7 million in 2024, then soared by 46.18% to $892.7 million in 2025, then advanced by 9.9% to $981.0 million in 2026.
• The last three Work In Process figures came in at $981.0 million (Q1 2026), $892.7 million (Q4 2025), and $885.4 million (Q3 2025), per Business Quant data.

Peer Comparison